Skip to main content
SpringerLink
Log in

Sibrafiban

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Sibrafiban is the orally administered, nonpeptide, double-prodrug of Ro 44-3888 which is a selective glycoprotein IIb/IIIa receptor antagonist. It is currently undergoing clinical trials for secondary prevention of cardiac events in patients stabilised after acute coronary syndromes.

  • ▴ In a phase II dose-finding study (TIMI 12) in patients stabilised after a myocardial infarction (MI) or an episode of unstable angina, there was a dose-dependent inhibition of platelet aggregation which correlated closely with the plasma concentration of the total active drug.

  • ▴ An ongoing phase III study (SYMPHONY) compares the effects of sibrafiban on cardiac events with that of aspirin in patients stabilised after a Q wave MI or an episode of unstable angina.

  • ▴ This large trial uses twice daily dosage regimens to produce the plasma concentrations which were associated with less bleeding in the earlier dose-ranging trial.

  • ▴ A long term (minimum duration 12 months) phase III study (2nd SYMPHONY) is under way to compare the effects of sibrafiban on cardiac events with those of aspirin in patients stabilised after an MI or an episode of unstable angina.

  • ▴ The most common adverse events associated with sibrafiban include bleeding, with minor haemorrhages occurring more often than with aspirin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Topol EJ, Califf R, Van de Werf F. Sibrafiban versus aspirin to yield maximum protection from ischaemic heart events post acute coronary syndromes (The SYMPHONY trial). Hoffmann-La Roche, clinical study protocol, 1997

  2. Weiler T, Alig L, Beresini M, et al. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39(16): 3139–47

    Article  Google Scholar 

  3. Alig L, Edenhofer A, Hadváry P, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393–407

    Article  PubMed  CAS  Google Scholar 

  4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995 Jun 8; 332: 1553–9

    Article  PubMed  CAS  Google Scholar 

  5. Yun DD, Alpert JS. Acute coronary syndromes. Cardiology 1997; 88: 223–37

    Article  PubMed  CAS  Google Scholar 

  6. Refino CJ, Modi NB, Bullens S, et al. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost 1998 Jan; 79: 169–76

    PubMed  CAS  Google Scholar 

  7. Modi NB, Lin YS, Reynolds T, et al. Pharmacokinetics and pharmacodynamics of Ro 48-3657, an orally active fibrinogen receptor antagonist, administered with heparin, aspirin and recombinant tissue-type plasminogen activator in beagles [abstract]. Pharm Res 1996 Sep; 13 Suppl.: 485

    Article  Google Scholar 

  8. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998 Feb 3; 97: 340–9

    Article  PubMed  CAS  Google Scholar 

  9. F. Hoffman-La Roche Ltd. A randomised, double-blind, long-term, aspirin-controlled trial with two dosage regimens of sibrafiban (Ro 48-3657), an oral platelet glycoprotein IIb/IIIa antagonist, in patients following an Acute Coronary Syndrome. Clinical study protocol, 1998

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Mukta Dooley & Karen L. Goa

Authors
  1. Mukta Dooley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mukta Dooley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dooley, M., Goa, K.L. Sibrafiban. Drugs 57, 225–230 (1999). https://doi.org/10.2165/00003495-199957020-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957020-00012

Keywords

Search

Navigation